Perfint Healthcare: Company Profile, Founder, Products, MAXIO, ROBIO EX and Image-Guided Cancer Intervention Technology
Introduction
Perfint Healthcare Private Limited is an Indian medical-technology company specializing in image-guided interventional procedures, medical robotics and technology for minimally invasive cancer interventions.
Unlike conventional medical-equipment manufacturers that mainly produce X-ray machines, ECG machines, ventilators or laboratory analysers, Perfint focuses on a much more specialized area: helping physicians plan, target, navigate and verify minimally invasive procedures using CT and PET-CT imaging.
Its technologies are particularly relevant to interventional oncology, where doctors may perform procedures such as tumor biopsy, tumor ablation, drainage and other image-guided interventions without requiring conventional open surgery.
The company’s current website identifies MAXIO® and ROBIO® EX as its principal products. It describes Perfint as a world leader in planning and targeting solutions for image-guided interventional procedures.
Perfint Healthcare Company Details
Company Detail Information Company Name Perfint Healthcare Private Limited Industry Medical Technology / Medical Robotics Main Field Image-Guided Interventional Procedures Primary Application Oncology and minimally invasive interventions Legal Incorporation 22 June 2005 Headquarters Chennai, Tamil Nadu, India Company Type Private Limited / Privately Held Founder & CEO Nandakumar Subburaman Current CEO Nandakumar S. Current Director Gopalkrishna Kulkarni Major Products MAXIO® and ROBIO® EX Major Technologies CT-guided robotic positioning, treatment planning and navigation International Office Redmond, Washington, USA Major Clinical Focus Tumor biopsy, ablation, drainage, FNAC and image-guided interventions
The legal entity Perfint Healthcare Private Limited was incorporated on 22 June 2005, according to company-registration records. Some business profiles describe the operating healthcare company as being founded in 2005, while LinkedIn lists 2010 as its founded date; for a formal company article, the MCA-linked incorporation date of 22 June 2005 is the more precise legal date.
Who Founded Perfint Healthcare?
Nandakumar Subburaman is identified publicly as the founder and CEO of Perfint Healthcare.
The company’s current leadership page lists Nandakumar S. as Chief Executive Officer, while external company profiles identify him as the company’s founder and CEO.
The company grew around the idea of using computer-assisted planning and robotic positioning to make difficult image-guided interventions more predictable and precise.
Nandakumar’s work in this field has also received recognition. Perfint’s official awards page lists a TiECON Next-Gen Entrepreneur of the Year recognition for him in 2012.
Who Owns Perfint Healthcare?
Perfint Healthcare is a privately held company, rather than a publicly listed company.
Publicly available company information identifies Nandakumar Subburaman as its founder, while corporate records list directors including Nandakumar Subburaman and Gopal Krishna Kulkarni.
Perfint has also received institutional venture investment. A Government of India medical-device industry report identifies investors including:
- Accel India Venture Fund
- IDG Ventures India Fund
- Norwest Venture Partners X LP
The same government report identifies Perfint as a Chennai-based medical-device company developing CT-guided robotic positioning technology and MAXIO.
Therefore, it would be inaccurate to simply describe Perfint as a company owned entirely by one individual. It is a privately held venture-backed medical-technology company.
What Does Perfint Healthcare Manufacture?
Perfint’s products are very different from ordinary hospital equipment.
The company’s main technology portfolio is built around image-guided intervention.
Its current website prominently lists:
1. MAXIO®
A physician-controlled stereotactic accessory for CT-guided procedures.
2. ROBIO® EX
A CT and PET-CT guided robotic positioning system for tumor targeting and tool placement.
The company also has technology associated with NAVIOS, a visualisation and treatment-planning platform for interventional oncology procedures.
How Many Products Does Perfint Healthcare Have?
This needs to be explained carefully.
Perfint’s current official website publicly highlights two primary commercial systems:
- MAXIO®
- ROBIO® EX
In addition, its website contains a NAVIOS workflow/planning platform.
Older technology from the company also includes PIGA-CT, an earlier robotic five-axis needle-guidance system that formed part of Perfint’s technology development history. A published clinical technical note describes PIGA-CT as a robotic five-axis guide arm and planning console developed by Perfint.
Therefore, it would be misleading to claim that Perfint manufactures hundreds of different medical devices.
Its business is based around a small number of highly specialized robotic and software-assisted interventional systems, with accessories and disposable components supporting the procedures.
1. MAXIO®
What Is MAXIO?
MAXIO® is one of Perfint Healthcare’s flagship technologies.
The company describes MAXIO as an image-guided, physician-controlled stereotactic accessory to a CT system.
It is designed to help physicians plan and target instruments during CT-guided percutaneous procedures involving organs and anatomical structures in the:
- Thorax
- Abdomen
- Pelvis
MAXIO can assist with procedures such as:
- Tumor ablation
- Biopsy
- Drainage
- Fine-needle aspiration
- Other CT-guided percutaneous interventions
Is MAXIO an Autonomous Cancer-Surgery Robot?
No.
This is a very important distinction.
MAXIO is described by Perfint as physician controlled.
The system helps with:
- Planning
- Target selection
- Instrument positioning
- Trajectory guidance
- Image registration
- Verification
The physician still performs the actual procedure and manually advances the instrument or probe through the guide.
Perfint’s workflow specifically describes the physician manually advancing each probe after the stereotactic arm positions the probe guide.
So MAXIO should not be described as a completely autonomous cancer-treatment robot.
How MAXIO Works
A typical workflow involves four major stages.
Step 1 — Setup
MAXIO is positioned next to the CT scanner and registered to the CT table.
Perfint’s InstaReg™ technology assists with registration of the system.
Step 2 — Planning
CT images are transferred to the system.
The physician can:
- Segment the target
- Identify no-go areas
- Define tumor margins
- Plan instrument trajectories
- Visualize the target in 2D and 3D
- Plan multiple instruments
The system can plan up to six instruments in its described workflow.
Step 3 — Procedure
The stereotactic arm positions the instrument guide.
The physician then manually advances the probe or needle through the guide.
Step 4 — Verification
After the procedure, image registration can be used to compare pre- and post-treatment images.
For tumor ablation, this can help determine whether the planned ablation volume adequately covers the target.
MAXIO for Cancer Treatment
MAXIO is particularly relevant to percutaneous tumor ablation.
A physician can use image guidance to position an ablation probe into a tumor.
Depending on the clinical situation, different energy-based ablation technologies can be used, including:
- Radiofrequency ablation
- Microwave ablation
- Irreversible electroporation
Perfint’s case material includes liver-tumor procedures using microwave ablation and other technologies.
The system itself does not necessarily generate the ablation energy. Instead, it assists with planning, positioning and targeting the instrument used for the treatment.
MAXIO for Tumor Biopsy
Cancer diagnosis often requires obtaining tissue from a suspicious lesion.
A CT-guided biopsy involves inserting a needle through the body and directing it toward the lesion.
Perfint’s technology can help plan the needle trajectory and guide the physician toward the target.
The company’s published workflow includes biopsy among the procedures supported by MAXIO.
MAXIO for Drainage and FNAC
The system can also support other percutaneous procedures.
These include:
- Drainage
- Fine-needle aspiration cytology (FNAC)
- Needle-based interventions
The exact procedure depends on the patient’s condition and the physician’s treatment plan.
MAXIO and Difficult Tumor Locations
One of the main advantages of robotic positioning technology is its usefulness when a lesion is:
- Deep inside an organ
- Close to critical structures
- Difficult to access
- Located at an unusual angle
Perfint’s case studies include a liver tumor located close to the heart and another lesion located near a major portal vein. The company describes MAXIO as being used to plan the trajectory and assess the planned ablation coverage.
MAXIO and Radiation Exposure
CT-guided procedures require imaging to confirm instrument position.
Repeated CT scans or repeated needle adjustments can increase procedure time and radiation exposure.
Perfint’s published material describes robotic assistance as potentially reducing:
- Needle manipulations
- Confirmatory scans
- Procedure time
- Radiation exposure
A published study listed by Perfint found reduced radiation dose, confirmatory scans and needle manipulations with CT-guided robotic positioning compared with manual positioning in a preclinical liver model, while maintaining equivalent targeting accuracy.
These findings should not be interpreted as guaranteeing a specific reduction for every patient or procedure.
2. ROBIO® EX
What Is ROBIO EX?
ROBIO® EX is another major Perfint Healthcare product.
The company describes it as a:
CT & PET-CT guided robotic positioning system
It is designed to assist with accurate tumor targeting and tool placement for thoracic and abdominal interventions.
ROBIO EX Applications
ROBIO EX can support procedures including:
- Tumor biopsy
- FNAC
- Pain management
- Drainage
- Tumor ablation
It can also be used for deep-seated lesions where special angulation is required.
ROBIO EX and PET-CT
One important difference is that ROBIO EX is designed for CT and PET-CT guided interventions.
PET-CT combines:
PET metabolic information + CT anatomical information.
This can be particularly useful in oncology because PET imaging can help identify metabolically active lesions while CT provides anatomical positioning.
ROBIO EX’s workflow allows the physician to select the target, identify an entry point, define a safe trajectory and guide the instrument through the positioning system.
ROBIO EX Procedure Workflow
The general workflow is:
Target Selection
The physician selects the desired image slice and identifies the target.
Entry Point
The skin-entry point and needle length are selected.
Trajectory Planning
The software displays the planned trajectory and helps identify whether important structures are in the path.
Robotic Positioning
The robotic positioning mechanism helps align the instrument guide.
Manual Needle Advancement
The physician manually advances the needle through the guide.
Verification
A check scan can be performed to confirm the position before the intended procedure.
NAVIOS
Perfint’s website also describes NAVIOS as an integrated visualization and treatment-planning platform for interventional oncology therapies.
NAVIOS provides tools for:
- 2D/3D visualization
- Tumor segmentation
- Defining no-go regions
- Tumor-margin planning
- Multi-probe planning
- Ablation-volume visualization
- Intra-operative image registration
- Post-operative verification
- Patient reporting
The platform is described as supporting organ-specific workflows for liver, lung and renal ablation.
PIGA-CT: Perfint’s Earlier Technology
Before its current MAXIO and ROBIO branding, Perfint developed PIGA-CT.
A technical publication described PIGA-CT as:
- A robotic five-axis guide arm
- Computer planning console
- CT image integration
- Automated coordinate calculation
- Needle-guidance mechanism
The system was designed to calculate target and insertion coordinates from CT images and position the needle guide accordingly.
PIGA-CT is important because it shows the technological foundation from which Perfint’s later robotic image-guidance systems developed.
What Medical Procedures Can Perfint Technology Support?
Perfint’s systems are designed around image-guided percutaneous intervention.
Major applications include:
Cancer Biopsy
Obtaining tissue samples from suspicious lesions.
Tumor Ablation
Guiding probes used to destroy selected tumors using thermal or other ablation techniques.
Liver Tumor Treatment
Perfint’s case studies include microwave and radiofrequency ablation of liver tumors.
Lung Procedures
The company’s scientific publications and videos include CT-guided lung biopsy and lung tumor ablation.
Renal Tumors
Perfint showcases renal-tumor ablation cases.
Drainage
Image-guided placement of drainage instruments.
FNAC
Fine-needle aspiration procedures.
Pain Management
The company also lists image-guided pain-management applications.
Which Organs Can Be Treated?
Perfint’s technology is relevant to image-guided interventions involving areas such as:
- Liver
- Lung
- Kidney
- Abdomen
- Thorax
- Pelvis
MAXIO’s official description specifically identifies procedures involving organs and structures in the thorax, abdomen and pelvis.
The actual suitability of the technology depends on the lesion, anatomy, procedure and physician.
Does Perfint Make Cancer Treatment Machines?
Yes, but this needs a precise explanation.
Perfint makes image-guidance and robotic positioning technology used during cancer interventions.
It does not manufacture a conventional chemotherapy machine.
It also does not replace:
- Oncologists
- Interventional radiologists
- Surgeons
- CT scanners
- Ablation generators
Instead, its technology works alongside imaging systems and interventional instruments.
Does MAXIO Replace a CT Scanner?
No.
MAXIO is an accessory system designed to work with a CT system.
Perfint specifically describes MAXIO as an image-guided stereotactic accessory to a CT system.
Therefore, a hospital needs appropriate imaging infrastructure for the system to be used.
Is ROBIO EX a Fully Autonomous Robot?
No.
ROBIO EX is a robotic positioning system.
It assists the physician with target positioning and trajectory guidance, but the physician performs the procedure.
Perfint’s workflow specifically states that the physician manually advances the needle through the probe guide.
FDA Approval and Regulatory Status
Perfint states that MAXIO is a US FDA 510(k)-cleared device.
This is significant because FDA 510(k) clearance indicates that the device has been cleared for the applicable intended use under the relevant regulatory pathway.
Perfint’s external company profile also states that its products are CE marked.
However, regulatory clearance can differ between product versions and countries, so each device’s current regulatory status should be checked separately.
Manufacturing and Company Locations
Perfint’s current official contact information lists its Indian office at:
Perfint Healthcare Pvt. Ltd.
Okkiyam, Thoraipakkam,
Chennai, Tamil Nadu, India.
The company also lists:
Perfint Healthcare Corporation
Redmond, Washington, USA.
This gives the company an India–United States operational footprint.
International Presence
Perfint is not limited to the Indian market.
Its website contains case studies and installations from multiple countries.
Examples listed by the company include:
- India
- United Kingdom
- Russia
- Vietnam
- Australia
- Germany
- China
- Malaysia
- United States
The company website specifically documents installations of MAXIO and ROBIO EX in locations including AIIMS Jodhpur, Vietnam and Russia, while its case material also references hospitals in the UK and Australia.
Perfint’s earlier public company profile stated that its systems had been used in hospitals in the United States, India, Germany and Russia.
How Many Hospitals Use Perfint Systems?
Perfint’s current website does not provide a single up-to-date worldwide installed-base number on its public homepage.
Therefore, it would be unsafe to publish an exact current number of hospitals using MAXIO or ROBIO EX without a company-provided current figure.
The website does, however, document installations and clinical use in multiple international hospitals.
Company Employees
Public sources give different employee estimates.
LinkedIn currently places Perfint in the 51–200 employee company-size category, while its public profile displays approximately 155 associated employees.
Because employee counts change and LinkedIn figures are not audited company filings, the article should treat this as an approximate public-profile figure rather than an exact official headcount.
Research and Development
Research and development is central to Perfint’s business.
The company’s scientific resources include studies covering:
- CT-guided biopsy
- Robotic liver-tumor ablation
- Lung biopsy
- Radiofrequency ablation
- Microwave ablation
- Irreversible electroporation
- Pain-management interventions
- Robotic needle positioning
Perfint maintains a dedicated scientific-publication section on its website containing clinical and preclinical research related to its technology.
Major Awards and Recognition
Perfint Healthcare has received several technology and innovation awards.
Fast Company Recognition — 2015
Perfint was included in Fast Company’s Top 50 Innovative Companies list in 2015 and was recognized as the second most innovative healthcare company in the world in that year’s coverage for its cancer-robotics work.
FICCI R&D Award — 2014
Perfint received the FICCI R&D Award for MAXIO’s integrated visualization, treatment planning and robotic navigation technology for CT-guided tumor ablation.
Government of India Biotechnology Award
Perfint also received a Department of Biotechnology Product & Process Development & Commercialization Award for biomedical product development and commercialization.
Frost & Sullivan Product Innovation Award
The company received the Frost & Sullivan Product Innovation Award in 2009 for its PIGA-CT device.
Perfint and the Indian Medical-Device Industry
Perfint is an interesting example of an Indian company moving beyond conventional medical equipment into medical robotics and software-assisted interventional medicine.
A Government of India medical-device industry report specifically identified Perfint’s technology as:
- CT-guided robotic positioning system — ROBIO EX
- Automated device for planning, execution and confirmation of targeted tumor ablation — MAXIO
The report identified the company as founded in 2005 and based in Chennai.
Latest Product and Technology Developments
A key point for a current article is that Perfint’s public website does not show a clearly dated 2026 launch of an entirely new flagship medical machine.
Instead, its current technology portfolio continues to focus on:
- MAXIO
- ROBIO EX
- NAVIOS-related interventional oncology workflow
- CT-guided robotic targeting
- PET-CT guided targeting
- Tumor-ablation planning and verification
The company continues to publish clinical material and demonstrate applications of its robotic systems.
Its website’s current scientific resources include publications through February 2026, demonstrating ongoing documentation and clinical evidence activity around its technology.
Therefore, for a website article, it is more accurate to say that Perfint’s recent development is centered on continued advancement and clinical application of its MAXIO/ROBIO image-guided robotic platforms, rather than inventing a new 2026 product launch.
New and Emerging Application Areas
Perfint’s technology is being applied or studied in several expanding areas.
Liver Tumor Ablation
The company showcases microwave ablation and other liver-tumor procedures.
Lung Tumor Procedures
Its scientific resources include CT-guided lung biopsy and lung-tumor intervention.
Renal Tumor Ablation
Renal tumor treatment is another application shown in Perfint’s case material.
PET-CT Guided Intervention
ROBIO EX expands targeting capabilities into PET-CT-guided interventions.
Pain Management
The company also applies robotic image-guidance technology to selected interventional pain procedures.
What Makes Perfint Different?
Perfint’s key difference is its focus on the planning and targeting layer of interventional medicine.
A simplified treatment chain can be understood as:
CT/PET-CT → Target identification → Treatment planning → Robotic positioning → Needle/probe placement → Ablation/biopsy → Image verification
Perfint’s technology primarily assists with the middle part of this workflow.
That makes it complementary to:
- CT scanners
- PET-CT scanners
- Biopsy needles
- Microwave-ablation systems
- Radiofrequency-ablation systems
- IRE systems
- Other interventional instruments
Benefits for Physicians
Perfint highlights several potential benefits for physicians.
These include:
- More structured treatment planning
- 2D and 3D visualization
- Trajectory planning
- Multi-probe planning
- Robotic positioning
- Angulation and depth assistance
- Image registration
- Post-procedure verification
Benefits for Patients
The company’s patient-focused material highlights potential benefits associated with minimally invasive image-guided procedures, including:
- Smaller access routes compared with open surgery in appropriate procedures
- Potentially shorter procedures
- Reduced needle manipulation
- Reduced radiation exposure in some workflows
These are potential workflow benefits and should not be interpreted as guaranteed outcomes for every patient.
Perfint Healthcare Product Summary
Product/Technology Main Function Main Application MAXIO® CT-guided stereotactic positioning and planning Tumor ablation, biopsy, drainage, FNAC ROBIO® EX CT/PET-CT robotic positioning Tumor targeting, biopsy, ablation, drainage NAVIOS Visualization and treatment planning Interventional oncology PIGA-CT Earlier robotic needle-guidance platform CT-guided biopsy/intervention
Frequently Asked Questions
1. What is Perfint Healthcare?
Perfint Healthcare is an Indian medical-technology company specializing in image-guided interventional procedures, medical robotics and planning/targeting solutions, particularly for oncology and pain-management applications.
2. When was Perfint Healthcare established?
The legal company Perfint Healthcare Private Limited was incorporated on 22 June 2005 in Chennai.
3. Who founded Perfint Healthcare?
Nandakumar Subburaman is identified as the founder and CEO of Perfint Healthcare.
4. Who is the current CEO?
Perfint’s official leadership page currently lists Nandakumar S. as Chief Executive Officer.
5. Where is Perfint Healthcare headquartered?
Perfint Healthcare is headquartered in Chennai, Tamil Nadu, India. The company also lists a U.S. corporation in Redmond, Washington.
6. What does Perfint Healthcare manufacture?
Its major products are image-guided robotic and stereotactic systems used for CT and PET-CT guided interventions, particularly MAXIO and ROBIO EX.
7. What is MAXIO?
MAXIO is a physician-controlled stereotactic accessory for CT-guided procedures. It assists with planning, targeting, instrument positioning and post-procedure verification.
8. What is ROBIO EX?
ROBIO EX is a CT and PET-CT guided robotic positioning system designed to assist with tumor targeting and tool placement during procedures such as biopsy, FNAC, drainage and tumor ablation.
9. Is MAXIO an autonomous cancer robot?
No. It is a physician-controlled system. The robot assists with positioning and guidance, while the physician manually advances the instrument through the guide.
10. Does Perfint make CT scanners?
No. Perfint’s main products are accessories and robotic positioning/planning technologies designed to work with CT or PET-CT imaging systems.
11. Does Perfint make chemotherapy machines?
No. Its main focus is image-guided interventional technology rather than chemotherapy equipment.
12. Can Perfint technology be used for liver cancer?
Perfint’s systems are used to assist image-guided liver-tumor interventions, including procedures involving microwave and radiofrequency ablation.
13. Can Perfint technology be used for lung tumors?
Yes. The company’s scientific resources include CT-guided lung biopsy and lung-tumor intervention studies and case material.
14. Is MAXIO FDA approved?
Perfint states that MAXIO is a US FDA 510(k)-approved/cleared device for its applicable intended use.
15. How many products does Perfint have?
The current official website prominently lists MAXIO and ROBIO EX as its main products, while NAVIOS is described as a planning/workflow platform. Earlier technology includes PIGA-CT. It is therefore better to describe Perfint as having a small portfolio of specialized platforms rather than claiming a large number of individual products.
16. In which countries are Perfint products used?
Perfint’s website documents installations and clinical use in countries including India, the UK, Russia, Vietnam and Australia, with additional historical international use reported in Germany, the U.S. and other markets.
17. What is the latest Perfint product?
Perfint’s current public portfolio is centered on MAXIO and ROBIO EX. The company has not published a clearly dated 2026 launch of a completely new flagship system on its current website. Its recent activity is focused on continued clinical applications, scientific publications and development of image-guided intervention technologies.
Conclusion
Perfint Healthcare is a specialized Indian medical-technology company that has developed a distinctive position in image-guided cancer intervention and medical robotics.
Founded in 2005 and headquartered in Chennai, the company focuses on technologies that help physicians plan and accurately target minimally invasive procedures using CT and PET-CT imaging. Its most important current systems are MAXIO® and ROBIO® EX, supported by planning and visualization technologies such as NAVIOS.
MAXIO is designed to assist physicians with CT-guided procedures including tumor ablation, biopsy, drainage and FNAC. ROBIO EX extends robotic positioning into CT and PET-CT guided interventions for tumor targeting and tool placement.
The company’s technology is particularly relevant to interventional oncology, where physicians can use minimally invasive techniques to diagnose or treat selected tumors in organs such as the liver, lung and kidney.
Perfint’s development history—from the earlier PIGA-CT platform to MAXIO and ROBIO EX—also demonstrates the growth of Indian medical technology from conventional equipment toward robotics, 3D treatment planning, image registration and computer-assisted intervention.
For India’s medical-device industry, Perfint is therefore an important example of a company working on a highly specialized area where medical imaging, software, robotics and cancer treatment come together.
Medical-device indications and regulatory approvals vary by product and country. Perfint systems are intended to assist trained physicians and should be used according to the applicable regulatory authorization, instructions for use and clinical protocols.
